alogliptin News
Most Popular alogliptin Story
Takeda down 13 percent on drug delay concerns
Japanese drugmaker Takeda Pharmaceuticals saw its shares plunge 13 percent--the daily limit--in morning trading amid concerns that the company's diabetes drug candidate, alogliptin, faces regulatory Read more...
Latest Headlines
- August 28, 2009
- June 29, 2009
- June 5, 2009
- March 9, 2009
- October 10, 2008
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
